Ferumoxtran-10, A Superparamagnetic Iron Oxide as a Magnetic Resonance Enhancement Agent for Imaging Lymph Nodes: A Phase 2 Dose Study
Patricia A Hudginsa,
Yoshimi Anzaib,
Marie R Morrisc and
Maria A Lucasc
a Department of Radiology, Emory University School of Medicine, Atlanta, GA
b Department of Radiology, the University of Washington, School of Medicine, Seattle
c Department of Radiology, Advanced Magnetics, Inc, Cambridge, MA
View larger version (23K):
[in a new window]
|
FIG 1. Mean change in signal intensity over time in the blinded evaluation
A, With T1-weighted imaging.
B, With T2-weighted imaging.
C, With T2*-weighted (FFE-25) imaging.
D, With T2*-weighted (FFE-80) imaging.
| |
View larger version (123K):
[in a new window]
|
FIG 2. Axial nonenhanced MR images in a healthy volunteer
A, Gradient-echo (FFE-80) (120/7.8/1, 80° flip angle) image shows a small left submandibular node (arrow).
B, On the fast spin-echo T2-weighted (3500/120/1) image, the node (arrow) is difficult to visualize because it is nearly isointense to fat.
| |
View larger version (122K):
[in a new window]
|
FIG 3. Axial MR images obtained 36 hours after the intravenous administration of 2.6 mg. Fe/kg ferumoxtran-10 in the same volunteer as in Figure 2.
A, Gradient-echo (FFE-80) (120/7.8/1, 80° flip angle) image shows that the benign node is now homogeneously hypointense (white arrow). Note the multiple additional nodes, some of which are delineated by black arrows, all of which are better visualized now than before contrast enhancement.
B,T2-weighted (3500/120/1) image obtained at the same level as Figure 1B shows excellent contrast between the enhanced left submandibular node (arrow) and the subcutaneous fat.
| |
